IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis
- 31 May 2005
- journal article
- Published by Elsevier BV in Clinical Immunology
- Vol. 115 (2), 216-223
- https://doi.org/10.1016/j.clim.2005.01.011
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- High levels of neutralizing IL‐6 autoantibodies in 0.1% of apparently healthy blood donorsEuropean Journal of Immunology, 2004
- Bone Marrow Mast Cell Morphologic Features and Hematopoietic Dyspoiesis in Systemic Mast Cell DiseaseAmerican Journal of Clinical Pathology, 2001
- Interleukin-6 and selected plasma proteins in healthy persons of different agesNeurobiology of Aging, 1994
- Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus.The Journal of Experimental Medicine, 1992
- Biological and clinical aspects of interleukin 6Immunology Today, 1990
- Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.JCI Insight, 1990
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.JCI Insight, 1989
- Interleukin 6 gene expression in normal and neoplastic B cells.JCI Insight, 1989
- Systemic Mast Cell DiseaseMedicine, 1988
- Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomasNature, 1988